Related Experiment Video
Updated: Jul 10, 2026

A Rat Model of Pressure Overload Induced Moderate Remodeling and Systolic Dysfunction as Opposed to Overt Systolic Heart Failure
Published on: April 30, 2020
Susceptibility to systolic dysfunction in the myocardium from chronically infarcted spontaneously hypertensive rats
Gavin R Norton1, Demetri G A Veliotes, Oleg Osadchii
1Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, University of the Witwatersrand Medical School, 7 York Road, Parktown 2193, Johannesburg, South Africa. gavin.norton@wits.ac.za
Insights
Hypertensive hearts develop myocardial dysfunction in viable tissue after myocardial infarction (MI), independent of chamber dilation or cell death. This dysfunction impairs cardiac function, particularly under stress, revealing a reduced adrenergic inotropic reserve.
Area of Science:
- Cardiology
- Heart Failure Research
- Hypertension Studies
Background:
- Myocardial infarction (MI) can lead to long-term cardiac complications.
- The impact of pre-existing hypertension on post-MI myocardial function in noninfarcted tissue is not fully understood.
- Understanding these mechanisms is crucial for improving pump function after MI in hypertensive patients.
Purpose of the Study:
- To investigate myocardial dysfunction in viable, noninfarcted heart tissue following MI in hypertensive rats.
- To explore the underlying mechanisms contributing to this dysfunction.
- To assess the impact of these changes on overall cardiac pump function.
Main Methods:
- Spontaneous hypertensive rats (SHR) and normotensive Wistar-Kyoto (WKY) rats underwent MI or sham surgery.
- Left ventricular (LV) systolic function in noninfarcted regions was assessed using ultrasonic transducers and echocardiography.
- LV dilatation, wall stress, apoptosis (TUNEL), necrosis, and global systolic function (LV Ees) were evaluated, with and without isoproterenol challenge.
Main Results:
- Reduced LV systolic function was observed in the noninfarcted walls of infarcted hypertensive rats (SHR-MI) but not in normotensive infarcted rats (WKY-MI).
- This dysfunction occurred despite similar LV dilatation, wall thinning, apoptosis, and necrosis between SHR-MI and WKY-MI groups.
- Under isoproterenol challenge, SHR-MI rats showed significantly reduced LV Ees, indicating impaired systolic function compared to controls.
Conclusions:
- The hypertensive heart is susceptible to developing myocardial dysfunction in viable tissue post-MI.
- This dysfunction is not explained by increased chamber dilation, apoptosis, or necrosis.
- The findings suggest a compromised cardiac adrenergic inotropic reserve in hypertensive hearts after MI.
Abstract:
We explored whether the hypertensive heart is susceptible to myocardial dysfunction in viable noninfarcted tissue post-myocardial infarction (MI), the potential mechanisms thereof, and the impact of these changes on pump function. Six to seven months after the ligation of the left anterior descending coronary artery, left ventricular (LV) myocardial systolic function, as assessed from the percent shortening of the noninfarcted lateral wall segmental length determined over a range of filling pressures (ultrasonic transducers placed in the lateral wall in anaesthetized, open-chest, ventilated rats) and the percent thickening of the posterior wall (echocardiography), was reduced in infarcted spontaneous hypertensive rats (SHR-MI) (P < 0.05) but not in normotensive Wistar-Kyoto (WKY-MI) animals compared with corresponding controls [SHR-sham operations (Sham) and WKY-Sham]. This change in the regional myocardial function in SHR-MI, but not in WKY-MI, occurred despite a similar degree of LV dilatation (increased LV end-diastolic dimensions and volume intercept of the LV end-diastolic pressure-volume relation) in SHR-MI and WKY-MI rats and a lack of difference in LV relative wall thinning, LV wall stress, apoptosis [terminal deoxynucleotidyl transferase biotin-dUTP nick-end labeling (TUNEL)], or necrosis (pathological score) between SHR-MI and WKY-MI rats. Although the change in regional myocardial function in the SHR-MI group was not associated with a greater reduction in baseline global LV chamber systolic function [end-systolic elastance (LV E(es)) and endocardial fractional shortening determined in the absence of an adrenergic stimulus], in the presence of an isoproterenol challenge, noninfarct-zone LV systolic myocardial dysfunction manifested in a significant reduction in LV E(es) in SHR-MI compared with WKY-MI and SHR and WKY-Sham rats (P < 0.04). In conclusion, these data suggest that with chronic MI, the hypertensive heart is susceptible to the development of myocardial dysfunction, a change that cannot be attributed to excessive chamber dilatation, apoptosis, or necrosis, but which in turn contributes toward a reduced cardiac adrenergic inotropic reserve.
Related Concept Videos
Heart Failure II: Pathophysiology
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Pathophysiology of Heart Failure
Mitral Regurgitation I: Introduction
Hypertension II: Pathophysiology
